BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Mok WC, Wasser S, Tan T, Lim SG. Polo-like kinase 1, a new therapeutic target in hepatocellular carcinoma. World J Gastroenterol 2012; 18(27): 3527-3536 [PMID: 22826617 DOI: 10.3748/wjg.v18.i27.3527]
URL: https://www.wjgnet.com/1948-5182/full/v18/i27/3527.htm
Number Citing Articles
1
Zheng Fu, Donghua Wen. The Emerging Role of Polo-Like Kinase 1 in Epithelial-Mesenchymal Transition and Tumor MetastasisCancers 2017; 9(12): 131 doi: 10.3390/cancers9100131
2
Michael M.C. Lai, Wen‐Chi Su. Polo‐like‐kinase 1: A key cellular target for anti‐HBV therapy?Hepatology 2017; 66(6): 1719 doi: 10.1002/hep.29407
3
Peter Dietrich, Kim Freese, Abdo Mahli, Wolfgang Erwin Thasler, Claus Hellerbrand, Anja Katrin Bosserhoff. Combined effects of PLK1 and RAS in hepatocellular carcinoma reveal rigosertib as promising novel therapeutic “dual-hit” optionOncotarget 2018; 9(3): 3605 doi: 10.18632/oncotarget.23188
4
Ya-Hui Huang, Ying-Hsin Tseng, Wey-Ran Lin, George Hung, Tse-Ching Chen, Tong-Hong Wang, Wei-Chen Lee, Chau-Ting Yeh. HBV polymerase overexpression due to large core gene deletion enhances hepatoma cell growth by binding inhibition of microRNA-100Oncotarget 2016; 7(8): 9448 doi: 10.18632/oncotarget.7021
5
Julia Alejandra Pezuk, María Sol Brassesco, Andressa Gois Morales, Jaqueline Carvalho de Oliveira, Harley Francisco de Oliveira, Carlos Alberto Scrideli, Luiz Gonzaga Tone. Inhibition of Polo-Like Kinase 1 Induces Cell Cycle Arrest and Sensitizes Glioblastoma Cells to Ionizing RadiationCancer Biotherapy and Radiopharmaceuticals 2013; 28(7): 516 doi: 10.1089/cbr.2012.1415
6
Rodrigo F.E. Bogado, Julia A. Pezuk, Harley F. de Oliveira, Luiz G. Tone, María S. Brassesco. BI 6727 and GSK461364 suppress growth and radiosensitize osteosarcoma cells, but show limited cytotoxic effects when combined with conventional treatmentsAnti-Cancer Drugs 2015; 26(1): 56 doi: 10.1097/CAD.0000000000000157
7
Shufeng Wang, Xinzheng Wang, Xin Yang, Feng Liu, Jin Li, Weihua Li, Zhaofang Bai, Hongbo Wang, Jie Mao, Tingting Li, Kun He, Hongxia Wang. Comprehensive kinomic study via a chemical proteomic approach reveals kinome reprogramming in hepatocellular carcinoma tissuesPROTEOMICS 2022; 22(4) doi: 10.1002/pmic.202100141
8
Yingai Zhang, Shunlan Wang, Jingchuan Xiao, Hailong Zhou. Bioinformatics analysis to identify the key genes affecting the progression and prognosis of hepatocellular carcinomaBioscience Reports 2019; 39(2) doi: 10.1042/BSR20181845
9
Chelsea E. Cunningham, Mackenzie J. MacAuley, Frederick S. Vizeacoumar, Omar Abuhussein, Andrew Freywald, Franco J. Vizeacoumar. The CINs of Polo-Like Kinase 1 in CancerCancers 2020; 12(10): 2953 doi: 10.3390/cancers12102953
10
Jean Baptiste Gossart, Etienne Pascal, Florent Meyer, Emilie Heuillard, Mathieu Gonçalves, Francine Gossé, Eric Robinet, Benoît Frisch, Cendrine Seguin, Guy Zuber. Performance of Pyridylthiourea‐Polyethylenimine Polyplex for siRNA‐Mediated Liver Cancer Therapy in Cell Monolayer, Spheroid, and Tumor Xenograft ModelsGlobal Challenges 2017; 1(4) doi: 10.1002/gch2.201700013
11
Imane El Dika, Ho Yeong Lim, Wei Peng Yong, Chia-Chi Lin, Jung-Hwan Yoon, Manuel Modiano, Bradley Freilich, Hye Jin Choi, Tsu-Yi Chao, Robin K. Kelley, Joanne Brown, Jennifer Knox, Baek-Yeol Ryoo, Thomas Yau, Ghassan K. Abou-Alfa. An Open-Label, Multicenter, Phase I, Dose Escalation Study with Phase II Expansion Cohort to Determine the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Intravenous TKM-080301 in Subjects with Advanced Hepatocellular CarcinomaThe Oncologist 2019; 24(6): 747 doi: 10.1634/theoncologist.2018-0838
12
Xia-Qing Zhou, Ya-Ping Li, Shuang-Suo Dang. Precision targeting in hepatocellular carcinoma: Exploring ligand-receptor mediated nanotherapyWorld Journal of Hepatology 2024; 16(2): 164-176 doi: 10.4254/wjh.v16.i2.164
13
Kuo-Shyang Jeng, Chiung-Fang Chang, Wen-Juei Jeng, I-Shyan Sheen, Chi-Juei Jeng. Heterogeneity of hepatocellular carcinoma contributes to cancer progressionCritical Reviews in Oncology/Hematology 2015; 94(3): 337 doi: 10.1016/j.critrevonc.2015.01.009
14
Ariel Ka-Man Chow, Simon Wing-Lung Yau, Lui Ng. Novel molecular targets in hepatocellular carcinomaWorld Journal of Clinical Oncology 2020; 11(8): 589-605 doi: 10.5306/wjco.v11.i8.589
15
Mahmoud A. Younis, Ikramy A. Khalil, Hideyoshi Harashima. Gene Therapy for Hepatocellular Carcinoma: Highlighting the Journey from Theory to Clinical ApplicationsAdvanced Therapeutics 2020; 3(11) doi: 10.1002/adtp.202000087
16
Zhixian Liu, Qingrong Sun, Xiaosheng Wang. PLK1, A Potential Target for Cancer TherapyTranslational Oncology 2017; 10(1): 22 doi: 10.1016/j.tranon.2016.10.003
17
Sophie Cazanave, Alexei Podtelezhnikov, Kristian Jensen, Mulugeta Seneshaw, Divya P. Kumar, Hae-Ki Min, Prasanna K. Santhekadur, Bubu Banini, Adolfo Gabriele Mauro, Abdul M. Oseini, Robert Vincent, Keith Q. Tanis, Andrea L. Webber, Liangsu Wang, Pierre Bedossa, Faridoddin Mirshahi, Arun J. Sanyal. The Transcriptomic Signature Of Disease Development And Progression Of Nonalcoholic Fatty Liver DiseaseScientific Reports 2017; 7(1) doi: 10.1038/s41598-017-17370-6
18
Sara Ortica, Nadine Tarantino, Nathalie Aulner, Alain Israël, Neetu Gupta‐Rossi. The 4 Notch receptors play distinct and antagonistic roles in the proliferation and hepatocytic differentiation of liver progenitorsThe FASEB Journal 2014; 28(2): 603 doi: 10.1096/fj.13-235903
19
Bin Shi, Marc Abrams, Laura Sepp-Lorenzino. Expression of Asialoglycoprotein Receptor 1 in Human Hepatocellular CarcinomaJournal of Histochemistry & Cytochemistry 2013; 61(12): 901 doi: 10.1369/0022155413503662
20
Hongjun Yu, Chaoqun Wang, Shanjia Ke, Miaoyu Bai, Yanan Xu, Shounan Lu, Zhigang Feng, Baolin Qian, Yue Xu, Menghua Zhou, Zihao Li, Bing Yin, Xinglong Li, Yongliang Hua, Yongzhi Zhou, Shangha Pan, Yao Fu, Yong Ma. Identification of CFHR4 as a Potential Prognosis Biomarker Associated With lmmune Infiltrates in Hepatocellular CarcinomaFrontiers in Immunology 2022; 13 doi: 10.3389/fimmu.2022.892750
21
Yeonhwa Song, Su-Yeon Lee, Sanghwa Kim, Inhee Choi, Namjeong Kim, Jongmin Park, Haeng Ran Seo. HO-1089 and HO-1197, Novel Herbal Formulas, Have Antitumor Effects via Suppression of PLK1 (Polo-like Kinase 1) Expression in Hepatocellular CarcinomaCancers 2023; 15(3): 851 doi: 10.3390/cancers15030851
22
Zewen Song, Zhaomei Yu, Limin Chen, Zhijiao Zhou, Qiong Zou, Yang Liu. MicroRNA-1181 supports the growth of hepatocellular carcinoma by repressing AXIN1Biomedicine & Pharmacotherapy 2019; 119: 109397 doi: 10.1016/j.biopha.2019.109397